Genetics Startup LEXEO Therapeutics Raises $100 mln in Series B Funding

LEXEO Therapeutics, a genetics startup based in New York, has raised $100 million in Series B funding to revolutionize the treatment of cardiovascular and neurological conditions.

The funding round was co-led by D1 Capital Partners and Eventide Asset Management, counting with participation from investors like CAM Capital, Grey’s Creek Capital Partners, Verition Fund Management, Laurion Capital Management, Longitude Capital, and Omega Funds. Dan Sundheim, D1 Capital Partners’s Founder, commented on the round:

“We believe in LEXEO’s mission and are proud to invest in a company led by experts in gene therapy. We are impressed by the company’s pipeline and are delighted to support its continued growth as it strives to develop meaningful treatments for patients.”

LEXEO Therapeutics is an integrated clinical-stage gene therapy startup working on gene therapies for inherited cardiovascular and central nervous system (CNS) conditions. This investment will support LEXEO’s development of a preclinical pipeline for rare cardiovascular diseases and genetic causes of Alzheimer’s disease, while also strengthening the startup’s clinical leadership programs. 

The startup’s pipeline includes gene therapies treated with adeno-associated viruses, CLN2 Batten disease, and APOE4-related Alzheimer’s disease. It is also currently researching and developing more than 15 AAV-mediated gene therapy programs. Chief Executive Officer of LEXEO Therapeutics. Nolan Townsend, referred to these plans by stating:

“As we embark on our next phase of growth, we are highly encouraged by the support of this diverse range of long-term focused investors participating in our Series B financing. With this capital infusion, we plan to advance our clinical stage pipeline to meaningful near-term data catalysts while establishing portfolio leadership positions in cardiac gene therapy and the genetics of Alzheimer’s disease.”

With cardiovascular diseases representing the leading cause of death globally, therapies like the ones developed by the genetics startup have proven to be an increasingly popular approach toward their treatment. Several startups in the field have seen an increase in funding over the past years as a direct result of advances in the area of genetics which promise to revolutionize the healthcare industry.